Intravitreal bevacizumab for inflammatory choroidal neovascularization: Results from the Pan-American collaborative retina study group at 24 months

J. Fernando Arevalo, Alfredo Adan, Maria H. Berrocal, Juan V. Espinoza, Mauricio Maia, Lihteh Wu, Jose A. Roca, Hugo Quiroz-Mercado, Jose M. Ruiz-Moreno, Martin A. Serrano

Research output: Contribution to journalArticle

Abstract

Background: To evaluate the anatomical and functional outcomes of intravitreal bevacizumab (1.25 or 2.5 mg) in the treatment of inflammatory choroidal neovascularization at 24 months. Methods: We reviewed the clinical records of 22 consecutive patients (23 eyes) with choroidal neovascularization secondary to chorioretinal inflammatory disease in this interventional retrospective multicenter case series. Sixteen eyes (63.6%) received a dose of 1.25 mg of intravitreal bevacizumab, and 7 eyes (36.4%) received a dose of 2.5 mg of intravitreal bevacizumab. Results: At baseline, the mean best-corrected visual acuity was 0.68 logarithm of minimum angle of resolution (Early Treatment Diabetic Retinopathy Study chart = 20/100). After intravitreal bevacizumab, best-corrected visual acuity improved significantly to 0.41 logarithm of minimum angle of resolution (20/51), 0.42 logarithm of minimum angle of resolution (20/53), and 0.40 logarithm of minimum angle of resolution (20/50) at 6, 12, and 24 months, respectively (P < 0.05). Fourteen eyes (60.8%) received 1 injection. Central macular thickness by optical coherence tomography decreased from 375.3 μm (range: 240-634 μm) at baseline to 241.6 μm (range: 189-306 μm) at 24 months of follow-up (P < 0.0001). Conclusion: Intravitreal bevacizumab at doses of 1.25 mg and 2.5 mg seems to provide stability or improvement in best-corrected visual acuity, optical coherence tomography, and fluorescein angiogram in inflammatory choroidal neovascularization at 24 months. All patients were treated after the underlying uveitic condition was controlled.

Original languageEnglish (US)
Pages (from-to)353-363
Number of pages11
JournalRetina
Volume31
Issue number2
DOIs
StatePublished - Feb 1 2011

    Fingerprint

Keywords

  • Avastin
  • CNV
  • bevacizumab
  • choroidal neovascularization
  • inflammatory
  • intravitreal injections

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Arevalo, J. F., Adan, A., Berrocal, M. H., Espinoza, J. V., Maia, M., Wu, L., Roca, J. A., Quiroz-Mercado, H., Ruiz-Moreno, J. M., & Serrano, M. A. (2011). Intravitreal bevacizumab for inflammatory choroidal neovascularization: Results from the Pan-American collaborative retina study group at 24 months. Retina, 31(2), 353-363. https://doi.org/10.1097/IAE.0b013e3181ed8cec